The bill does not affect existing requirements related to safety, quality, and efficacy of the medicines in assessment of the therapeutic benefits and risks. Also, the bill does not affect the ability for conditions to be imposed on the use of a medicine where these are justified and consistent with the reasons for granting provisional consent. The bill will validate existing provisional consents, including the Pfizer COVID-19 vaccine. Validation will ensure that medicines currently granted provisional consent continue to be available to New Zealanders where there is deemed to be a clinical or public health need. I commend this bill to the House.